Division of Endocrinology and Metabolism, Department of Internal Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Department of Pharmacy, Shanghai Jiao Tong University School of Medicine, Affiliated Renji Hospital, Shanghai, China.
Metab Syndr Relat Disord. 2020 Apr;18(3):168-171. doi: 10.1089/met.2019.0109. Epub 2020 Feb 11.
Pioglitazone is an effective treatment option in clinical practice for managing type 2 diabetes mellitus. It is challenged by a lot of adverse effects, primarily body weight gain, peripheral edema, as well as congestive heart failure. This is a case of a 76-year-old woman with no evidence of cardiac disease, who developed edema as well as bilateral pleural effusion after using pioglitazone. She got a weight decrease and complete resolution of the pleural effusion after stopping use of pioglitazone and rational use of diuretics. Common side effects of pioglitazone have been widely reported. However, little attention was drawn on pleural effusion in diabetic patients with no pre-existing heart dysfunction. In this case, we show the use of pioglitazone results in pleural effusion, with emphasis on the clinical recognition and management.
吡格列酮是临床治疗 2 型糖尿病的有效治疗选择。它存在很多不良反应，主要是体重增加、外周水肿和充血性心力衰竭。这是一例 76 岁的女性病例，无心脏病证据，在使用吡格列酮后出现水肿和双侧胸腔积液。停用吡格列酮并合理使用利尿剂后，她的体重减轻，胸腔积液完全消退。吡格列酮的常见副作用已被广泛报道。然而，对于无原有心功能障碍的糖尿病患者出现胸腔积液，很少引起关注。在这种情况下，我们展示了吡格列酮的使用会导致胸腔积液，并强调了临床识别和管理。
